Stock Research for ARRY


Featured Broker: Ally Invest

Get the due diligence for another stock.


ARRY Stock Chart & Research Data

The ARRY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARRY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ARRY Due diligence Resources & Stock Charts

The ARRY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARRY Detailed Price Forecast - CNN Money CNN View ARRY Detailed Summary - Google Finance
Yahoo View ARRY Detailed Summary - Yahoo! Finance Zacks View ARRY Stock Research & Analysis -

Stock Analysis

TradeIdeas View ARRY Trends & Analysis - Trade-Ideas Barrons View ARRY Major Holders - Barrons
NASDAQ View ARRY Call Transcripts - NASDAQ Seeking View ARRY Breaking News & Analysis - Seeking Alpha
Spotlight View ARRY Annual Report - OTC Report View ARRY OTC Short Report -
TradeKing View ARRY Fundamentals - TradeKing Charts View ARRY SEC Filings - Bar Chart
WSJ View Historical Prices for ARRY - The WSJ Morningstar View Performance/Total Return for ARRY - Morningstar
MarketWatch View the Analyst Estimates for ARRY - MarketWatch CNBC View the Earnings History for ARRY - CNBC
StockMarketWatch View the ARRY Earnings - StockMarketWatch MacroAxis View ARRY Buy or Sell Recommendations - MacroAxis
Bullish View the ARRY Bullish Patterns - American Bulls Short Pains View ARRY Short Pain Metrics -

Social Media Mentions

StockTwits View ARRY Stock Mentions - StockTwits PennyStocks View ARRY Stock Mentions - PennyStockTweets
Twitter View ARRY Stock Mentions - Twitter Invest Hub View ARRY Investment Forum News - Investor Hub
Yahoo View ARRY Stock Mentions - Yahoo! Message Board Seeking Alpha View ARRY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ARRY - Insider Cow View Insider Transactions for ARRY - Insider Cow
CNBC View ARRY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARRY - OTC Markets
Yahoo View Insider Transactions for ARRY - Yahoo! Finance NASDAQ View Institutional Holdings for ARRY - NASDAQ

Stock Charts

FinViz View ARRY Stock Insight & Charts - StockCharts View ARRY Investment Charts -
BarChart View ARRY Stock Overview & Charts - BarChart Trading View View ARRY User Generated Charts - Trading View

Latest Financial News for ARRY

European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma
Posted on Thursday September 20, 2018

- European Commission approval applies to all 28 European Union member states, Liechtenstein, Iceland and Norway - - Approval is based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median ...

See what the IHS Markit Score report has to say about Array Biopharma Inc.
Posted on Thursday September 20, 2018

Over the last month, growth of ETFs holding ARRY is favorable, with net inflows of $4.78 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.

Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology
Posted on Thursday September 13, 2018

- BRAFTOVI + MEKTOVI demonstrated a median overall survival of 33.6 months in patients with advanced BRAF-mutant melanoma in Phase 3 COLUMBUS trial - BOULDER, Colo. , Sept. 13, 2018 /PRNewswire/ --   Array ...

How Analysts View Amicus Therapeutics in September
Posted on Wednesday September 12, 2018

On September 10, Amicus Therapeutics (FOLD) announced the regulatory and clinical progress of its AT-GAA development program for Pompe disease. The company has met with the FDA to discuss the regulatory trajectory for AT-GAA, and the FDA has provided final written minutes of the meeting. Amicus Therapeutics has implemented the suggestions of the FDA and the European Medicines Agency for the study.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.